Ten people with fragile X syndrome are set to receive microdoses of psilocybin after Vancouver-based biotech company Nova Mentis gained approval from Health Canada to start a phase 2A open-label trial in partnership with KGK Science. Miniscule doses of psilocybin rescue a cognitive deficit in rats modeling fragile X syndrome, according to a December study from a team including Nova Mentis scientists.
